Table 1.
Patient characteristics and descriptive statistics
| Variable | All patients (n = 128) |
|---|---|
| Median Age, years (range) | 61.0 (34.0–87.0) |
| Sex, n (%) | |
| Male | 103 (80.5) |
| Female | 25 (19.5) |
| Median Body Mass Index (BMI), Kg/m2 (range) | 24.7 (17.1–35.9) |
| Laterality, n (%) | |
| Right | 60 (46.9) |
| Left | 68 (53.1) |
| Clinical Symptoms, n (%) | |
| Hematuria | 53 (41.4) |
| Osphyalgia | 17 (13.3) |
| Paraneoplastic Syndrome (Fever, Anemia, Hypercalcemia, Emaciation) |
18 (14.1) |
| Asymptomatic | 55 (42.9) |
| MaximumTumor Size, cm (range) | 7.4 (2.7~19.0) |
| Perirenal Fat Invasion, n (%) | |
| Yes | 52 (40.6) |
| No | 76 (59.4) |
| Tumor Necrosis, n (%) | |
| Yes | 33 (25.8) |
| No | 95 (74.2) |
| pN+, n (%) | |
| Yes | 9 (7.0) |
| No | 121 (93.0) |
| Pathological Type, (%) | |
| Clear Cell Carcinoma | 126 (98.4) |
| Chromophobe Cell Carcinoma | 1 (0.8) |
| Type II Papillary Cell Carcinoma | 1 (0.8) |
| Fuhrman Grade (Clear Cell Carcinoma), n (%) | |
| G1 | 7 (5.6) |
| G2 | 46 (36.5) |
| G3 | 52 (41.3) |
| G4 | 21 (16.6) |
| Sarcomatoid Differentiation, n (%) | |
| Yes | 26 (20.8) |
| No | 102 (79.2) |
| Friable RVTT, n (%) | |
| Yes | 23 (18.0) |
| No | 105 (82.0) |
| Median Bleeding Volume, ml (range) | 150 (30~4000) |
| Median Volume of Blood Transfusion, ml (range) | 1200 (200~4500) |
| Postoperative Adjuvant Therapy, n (%) | |
| Cytokine or Targeted Therapy | 60 (46.9) |
| Active surveillance | 68 (53.1) |
| Postoperative Local Recurrence/Metastasis, n (%) | |
| Lung Metastasis | 39 (30.5) |
| Bone Metastasis | 7 (5.5) |
| Local Recurrence | 4 (3.1) |
| Thyroid Metastasis | 2 (1.6) |
| Brain Metastasis | 1 (0.8) |
| Scalp Metastasis | 1 (0.8) |
| Abdominal Wall Metastasis | 1 (0.8) |
| Lymph Node Metastasis | 1 (0.8) |
| Multiple Organ Metastasis | 3 (2.3) |